New drug approach tested before cancer surgery
NCT ID NCT07352280
Summary
This study observes how well the drug tislelizumab works when given before surgery to patients with a specific type of stage II or III colorectal cancer. About 30 patients will receive three cycles of the drug, then have surgery, and be followed for five years. The goal is to see if this approach helps eliminate cancer cells before the operation and improves long-term outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER (DMMR/MSI-H CRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Undefined, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.